Brain Mapping Limits Refined in Surgery
Carnegie Mellon University researchers refined understanding of brain mapping limits during "awake brain mapping" surgery for brain tumors. The study reveals both the power and current limitations of identifying and preserving critical brain regions responsible for language, movement, and quality of life. The findings have implications for neurosurgeons, patients, and neuroscience research into the variability of human brain function.
The new methodology moves beyond a simple binary approach—where a surgeon tests if a brain region is critical or not—to a more nuanced, continuous measurement. Researchers Bradford Mahon and Raouf Belkhir led the effort, analyzing subtle hesitations or slight errors in a patient's real-time responses to electrical stimulation, providing a much richer, more detailed functional map. This technique refines a procedure with a long history, known as awake craniotomy. Surgeons have performed these operations since at least the 1980s to remove tumors near "eloquent" brain areas controlling functions like language or movement. The standard method involves stimulating the brain's surface with a small electrical probe and observing the patient's response to tasks like counting or naming objects. Historically, surgeons treated any stimulation that didn't cause an obvious error as a "safe" area for resection. The Carnegie Mellon study challenges this, showing that even in the absence of overt errors, the speed and accuracy of a patient's response can indicate a brain area's importance. This more granular data is critical because the functional organization of the brain varies significantly from person to person. This high degree of individual variability is a major challenge in neurosurgery. Key functional zones can shift due to genetics, development, or the presence of a slow-growing tumor, a phenomenon related to the brain's ability to reorganize itself, known as neuroplasticity. Accurately mapping these unique brain layouts is essential to removing as much of a tumor as possible while preserving a patient's quality of life. The research has led to the creation of MindTrace, a software platform and CMU spinoff company co-founded by Mahon. The platform is designed to integrate various data streams, including advanced imaging and the new, fine-grained behavioral measures, into a unified 3D map for surgeons. MindTrace aims to help clinical teams simulate different surgical plans and predict cognitive outcomes before and during the operation. The technology is already in use for research purposes at six major medical centers in the United States, with the goal of creating a large dataset to train machine learning models that can forecast patient outcomes with increasing accuracy.
